DOP1B

Summary

DOP1B (DOP1 leucine zipper like protein B, HGNC:1291) is a protein-coding gene on chromosome 21q22.12, encoding Protein DOP1B (Q9Y3R5). May play a role in regulating membrane trafficking of cargo proteins.

Involved in cognition and embryonic pattern specification. Located in early endosome membrane.

Source: NCBI Gene 9980 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 482 total
• Phenotypes (HPO): 1
• MANE Select transcript: NM_001320714

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1291
Approved symbol	DOP1B
Name	DOP1 leucine zipper like protein B
Location	21q22.12
Locus type	gene with protein product
Status	Approved
Aliases	KIAA0933
Ensembl gene	ENSG00000142197
Ensembl biotype	protein_coding
OMIM	604803
Entrez	9980

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 6 protein_coding, 2 nonsense_mediated_decay, 1 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000399151, ENST00000463668, ENST00000492760, ENST00000685394, ENST00000691173, ENST00000693273, ENST00000903972, ENST00000937467, ENST00000943075, ENST00000943076

RefSeq mRNA: 2 — MANE Select: NM_001320714 NM_001320714, NM_005128

CCDS: CCDS13643

Canonical transcript exons

ENST00000691173 — 37 exons

Exon	Start	End
ENSE00000952867	36219372	36219492
ENSE00000952868	36223231	36223350
ENSE00000952869	36225565	36225667
ENSE00000952870	36227686	36227877
ENSE00000952871	36230450	36231134
ENSE00000952872	36232804	36233075
ENSE00000952873	36237262	36237414
ENSE00000952874	36238601	36238701
ENSE00000952875	36239765	36239955
ENSE00001044179	36263748	36263814
ENSE00001044187	36214442	36214556
ENSE00001044194	36164708	36164871
ENSE00001044198	36281483	36281611
ENSE00001044199	36245048	36246677
ENSE00001044202	36263546	36263650
ENSE00001044208	36280285	36280346
ENSE00001044212	36214081	36214190
ENSE00001044224	36277021	36277100
ENSE00001044228	36260677	36260732
ENSE00001044233	36211974	36212097
ENSE00001044238	36200331	36200501
ENSE00001044241	36288014	36288150
ENSE00001044242	36289045	36289206
ENSE00001044254	36288756	36288811
ENSE00001044258	36278209	36278355
ENSE00001044260	36292104	36292233
ENSE00001044263	36277975	36278084
ENSE00001044279	36199070	36199251
ENSE00001238145	36270013	36270157
ENSE00001238304	36293320	36294274
ENSE00003464096	36253772	36253909
ENSE00003500617	36211553	36211651
ENSE00003504893	36248380	36248568
ENSE00003641468	36208715	36208904
ENSE00003649664	36251162	36251284
ENSE00003664197	36247517	36247628
ENSE00003932038	36156824	36156943

Expression profiles

Bgee: expression breadth ubiquitous, 224 present calls, max score 92.07.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 8.9165 / max 135.9408, expressed in 1681 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
188985	8.7078	1677
188986	0.2087	84

Top tissues by expression

292 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cortical plate	UBERON:0005343	92.07	gold quality
ganglionic eminence	UBERON:0004023	90.33	gold quality
rectum	UBERON:0001052	84.56	gold quality
cerebellar cortex	UBERON:0002129	84.21	gold quality
cerebellar hemisphere	UBERON:0002245	84.18	gold quality
right hemisphere of cerebellum	UBERON:0014890	83.29	gold quality
monocyte	CL:0000576	83.17	gold quality
cerebellum	UBERON:0002037	82.91	gold quality
mononuclear cell	CL:0000842	82.75	gold quality
leukocyte	CL:0000738	82.72	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	82.66	gold quality
minor salivary gland	UBERON:0001830	81.10	gold quality
saliva-secreting gland	UBERON:0001044	80.96	gold quality
muscle of leg	UBERON:0001383	80.67	gold quality
gastrocnemius	UBERON:0001388	80.28	gold quality
esophagus mucosa	UBERON:0002469	80.25	gold quality
body of stomach	UBERON:0001161	80.07	gold quality
hindlimb stylopod muscle	UBERON:0004252	80.03	gold quality
granulocyte	CL:0000094	79.87	gold quality
bone marrow cell	CL:0002092	79.58	gold quality
lower esophagus mucosa	UBERON:0035834	79.44	gold quality
stomach	UBERON:0000945	79.30	gold quality
transverse colon	UBERON:0001157	79.23	gold quality
jejunal mucosa	UBERON:0000399	79.14	gold quality
mouth mucosa	UBERON:0003729	78.94	gold quality
secondary oocyte	CL:0000655	78.68	gold quality
islet of Langerhans	UBERON:0000006	78.02	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	77.91	gold quality
skeletal muscle organ	UBERON:0014892	77.90	gold quality
muscle organ	UBERON:0001630	77.89	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.24

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

43 targeting DOP1B, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-512-3P	99.97	67.35	1049
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-539-5P	99.93	70.30	2855
HSA-MIR-4778-3P	99.93	70.40	1818
HSA-MIR-3671	99.90	73.04	3897
HSA-MIR-30A-3P	99.87	69.74	2928
HSA-MIR-30D-3P	99.87	69.92	2917
HSA-MIR-30E-3P	99.87	69.68	2942
HSA-MIR-4698	99.84	71.41	4303
HSA-MIR-4659A-3P	99.80	72.62	4248
HSA-MIR-4659B-3P	99.80	72.62	4248
HSA-MIR-4694-3P	99.79	69.53	2640
HSA-MIR-4802-3P	99.72	70.13	1273
HSA-MIR-545-5P	99.66	70.18	2308
HSA-MIR-1303	99.65	69.77	1662
HSA-MIR-3682-3P	99.58	67.63	865
HSA-MIR-2113	99.58	71.22	1521
HSA-MIR-7159-5P	99.53	72.12	2472
HSA-MIR-543	99.52	69.03	2595
HSA-MIR-3915	99.45	68.49	1905
HSA-MIR-504-3P	99.30	67.18	1745
HSA-MIR-4293	99.22	65.46	1263
HSA-MIR-6504-3P	99.17	69.31	2891
HSA-MIR-10399-5P	99.17	69.87	2610
HSA-MIR-323B-3P	99.14	68.89	725

Literature-anchored findings (GeneRIF, showing 6)

• The differentially expressed C21orf5 gene in the medial temporal-lobe system could play a role in Down syndrome. (PMID:12767918)
• C21orf5 selective expression in the key brain structures for learning and memory suggests that C21orf5 overexpression could participate in mental retardation pathogenesis in Down syndrome patients. (PMID:16276086)
• C21orf5, could play a role in brain morphogenesis and, when overexpressed, it could participate in neurological features and mental retardation observed in DS patients. (PMID:16303751)
• Results quantify and statistically analyze, for the first time, DOPEY2 expression variations in different regions of the Down syndrome human fetal brains and to compare them to corresponding normal brains. (PMID:19460634)
• an evolutionary conserved MON2:DOPEY2:ATP9A complex is required for SNX3 retromer mediation of Wntless sorting and Wnt secretion (PMID:30213940)
• A mutation in DOP1B identified as a probable cause for autosomal recessive Peters anomaly in a consanguineous family. (PMID:33273802)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	dop1b	ENSDARG00000055857
mus_musculus	Dop1b	ENSMUSG00000022946
rattus_norvegicus	Dop1b	ENSRNOG00000051204
drosophila_melanogaster	CG15099	FBGN0034400
caenorhabditis_elegans	pad-1	WBGENE00003905

Paralogs (1): DOP1A (ENSG00000083097)

Protein

Protein identifiers

Protein DOP1B — Q9Y3R5 (reviewed: Q9Y3R5)

All UniProt accessions (3): Q9Y3R5, A0A8I5KUN1, A0A8I5KWI7

UniProt curated annotations — full annotation on UniProt →

Function. May play a role in regulating membrane trafficking of cargo proteins. Together with ATP9A and MON2, regulates SNX3 retromer-mediated endosomal sorting of WLS away from lysosomal degradation.

Subunit / interactions. Homooligomer. Heterotrimer with ATP9A and MON2; this interaction is retromer-independent. Interacts with SNX3.

Subcellular location. Early endosome membrane. Golgi apparatus membrane.

Tissue specificity. Ubiquitously expressed. Overexpressed in lymphoblasts from Down syndrome patients.

Similarity. Belongs to the DOP1 family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9Y3R5-1	1	yes
Q9Y3R5-2	2

RefSeq proteins (2): NP_001307643, NP_005119 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR007249	DOP1_N	Domain
IPR040314	DOP1	Family
IPR056457	DOP1_C	Domain
IPR056458	TPR_DOP1_M	Domain
IPR056459	TPR_DOP1	Domain

Pfam: PF04118, PF24597, PF24598, PF24601

UniProt features (23 total): sequence variant 5, sequence conflict 5, region of interest 4, compositionally biased region 4, modified residue 3, chain 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9Y3R5-F1	72.36	0.19

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (3): 597, 1169, 556

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 174 (showing top): GOBP_COGNITION, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_UP, GOBP_VESICLE_MEDIATED_TRANSPORT, GOBP_REGULATION_OF_VESICLE_MEDIATED_TRANSPORT, GOCC_TRANS_GOLGI_NETWORK, MARTINEZ_RB1_TARGETS_DN, GOBP_EMBRYONIC_PATTERN_SPECIFICATION, GOBP_REGULATION_OF_CELLULAR_LOCALIZATION, DACOSTA_UV_RESPONSE_VIA_ERCC3_COMMON_DN, GOBP_GOLGI_TO_ENDOSOME_TRANSPORT, CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_5, GOBP_ENDOMEMBRANE_SYSTEM_ORGANIZATION, SCHLOSSER_SERUM_RESPONSE_DN, BROWN_MYELOID_CELL_DEVELOPMENT_UP

GO Biological Process (5): Golgi to endosome transport (GO:0006895), endoplasmic reticulum organization (GO:0007029), embryonic pattern specification (GO:0009880), protein transport (GO:0015031), cognition (GO:0050890)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (8): Golgi membrane (GO:0000139), endosome (GO:0005768), trans-Golgi network (GO:0005802), cytosol (GO:0005829), early endosome membrane (GO:0031901), extracellular exosome (GO:0070062), Golgi apparatus (GO:0005794), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
endomembrane system	2
cytoplasm	2
cellular anatomical structure	2
post-Golgi vesicle-mediated transport	1
intercellular transport	1
cytosolic transport	1
organelle organization	1
endomembrane system organization	1
pattern specification process	1
embryo development	1
transport	1
intracellular protein localization	1
establishment of protein localization	1
nervous system process	1
binding	1
Golgi apparatus	1
bounding membrane of organelle	1
cytoplasmic vesicle	1
Golgi apparatus subcompartment	1
early endosome	1
endosome membrane	1
extracellular vesicle	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

792 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
DOP1B	SLC35F2	Q8IXU6	645
DOP1B	MON2	Q7Z3U7	590
DOP1B	IMMP2L	Q96T52	557
DOP1B	RELN	P78509	542
DOP1B	CSMD1	Q96PZ7	531
DOP1B	MRPS6	P82932	517
DOP1B	CHRFAM7A	Q494W8	510
DOP1B	TMEM50B	P56557	488
DOP1B	HNRNPCL1	O60812	475
DOP1B	EVA1C	P58658	471
DOP1B	PAXBP1	Q9Y5B6	463
DOP1B	POFUT2	Q9Y2G5	449
DOP1B	ERBB4	Q15303	443
DOP1B	SYNJ1	O43426	431
DOP1B	TBATA	Q96M53	419

IntAct

34 interactions, top by confidence:

A	B	Type	Score
SDC2	PDPK1	psi-mi:“MI:0914”(association)	0.640
LAMP3	METTL15	psi-mi:“MI:0914”(association)	0.530
ATP1A1	SRC	psi-mi:“MI:0914”(association)	0.530
STK16	UNC119B	psi-mi:“MI:0914”(association)	0.530
ILVBL	SLC33A1	psi-mi:“MI:0914”(association)	0.530
TPTE	ILVBL	psi-mi:“MI:0914”(association)	0.350
P		psi-mi:“MI:0914”(association)	0.350
IMMP1L	EIF1AY	psi-mi:“MI:0914”(association)	0.350
YWHAH	SHTN1	psi-mi:“MI:0914”(association)	0.350
	HLA-C	psi-mi:“MI:0914”(association)	0.350
ATG16L1	ESYT2	psi-mi:“MI:0914”(association)	0.350
MGARP	BTAF1	psi-mi:“MI:0914”(association)	0.350
IGHM	ESYT2	psi-mi:“MI:0914”(association)	0.350
GPR182	METTL15	psi-mi:“MI:0914”(association)	0.350
NPTN	RTL8C	psi-mi:“MI:0914”(association)	0.350
FPR1	GPR89A	psi-mi:“MI:0914”(association)	0.350
DOP1B	FOXK1	psi-mi:“MI:0914”(association)	0.350
GPR182	SLC12A8	psi-mi:“MI:0914”(association)	0.350
CLEC2D	ESYT2	psi-mi:“MI:0914”(association)	0.350
HLA-DQA1	TMEM131L	psi-mi:“MI:0914”(association)	0.350
OPALIN	FAM171A2	psi-mi:“MI:0914”(association)	0.350
MFSD4A	UBXN8	psi-mi:“MI:0914”(association)	0.350
HLA-B	RAB29	psi-mi:“MI:0914”(association)	0.350
MFSD4B	XPOT	psi-mi:“MI:0914”(association)	0.350
SLC27A4	IPO5	psi-mi:“MI:0914”(association)	0.350
SLC2A2	ESYT2	psi-mi:“MI:0914”(association)	0.350
SLC2A9	EXOC5	psi-mi:“MI:0914”(association)	0.350
SLC30A4	ESYT2	psi-mi:“MI:0914”(association)	0.350

BioGRID (62): DOPEY2 (Affinity Capture-MS), DOPEY2 (Affinity Capture-MS), DOPEY2 (Affinity Capture-MS), DOPEY2 (Affinity Capture-MS), DOPEY2 (Affinity Capture-MS), DOPEY2 (Affinity Capture-MS), DOPEY2 (Affinity Capture-RNA), DOPEY2 (Protein-RNA), DOPEY2 (Affinity Capture-MS), DOPEY2 (Proximity Label-MS), DOPEY2 (Affinity Capture-MS), DOPEY2 (Proximity Label-MS), DOPEY2 (Proximity Label-MS), DOPEY2 (Proximity Label-MS), DOPEY2 (Proximity Label-MS)

ESM2 similar proteins: A0JMD0, A1A535, A1ZAB5, A2AIV2, A8E7C5, A8PJX4, A8XAA9, B0W2S0, B3MIW0, B3NPV8, B4GAM1, B4JW99, B4KT50, B4LQ23, B4MY63, B4P6P7, D3YVL2, E9PXF8, F4HS99, F4HZK4, F4J5S1, F4JKH6, O60502, O75153, O88379, P34466, P69735, Q0IHW8, Q0VA04, Q15042, Q17N71, Q291J5, Q5PQS3, Q5SW19, Q5TYW4, Q5U430, Q69YN4, Q6NTN5, Q6ZT12, Q7PZD5

Diamond homologs: Q3UHQ6, Q5JWR5, Q642P2, Q8BL99, Q9Y3R5, Q9Y7B3, A1ZBE8, Q292H2, Q9C0Z4, Q5WNI9, Q9XW10

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
DOP1B	“form complex”	“ATP9A-DOP1B-MON2, golgi transporter complex”	binding

Disease & clinical

Clinical variants and AI predictions

ClinVar

482 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	389
Likely benign	30
Benign	12

Top pathogenic / likely-pathogenic (0)

SpliceAI

5780 predictions. Top by Δscore:

Variant	Effect	Δscore
21:36164871:GGT:G	donor_loss	1.0000
21:36164873:T:G	donor_loss	1.0000
21:36200326:C:A	acceptor_gain	1.0000
21:36200498:ACAGG:A	donor_loss	1.0000
21:36200500:AGG:A	donor_loss	1.0000
21:36200502:GTGC:G	donor_loss	1.0000
21:36200503:T:G	donor_loss	1.0000
21:36208905:GT:G	donor_loss	1.0000
21:36208906:T:A	donor_loss	1.0000
21:36209923:AAAAT:A	acceptor_gain	1.0000
21:36214437:AATAG:A	acceptor_gain	1.0000
21:36214438:ATAG:A	acceptor_gain	1.0000
21:36214439:TAGG:T	acceptor_loss	1.0000
21:36214440:A:AG	acceptor_gain	1.0000
21:36214440:AG:A	acceptor_gain	1.0000
21:36214440:AGG:A	acceptor_gain	1.0000
21:36214441:G:GC	acceptor_gain	1.0000
21:36214441:GG:G	acceptor_gain	1.0000
21:36214441:GGG:G	acceptor_gain	1.0000
21:36214441:GGGT:G	acceptor_gain	1.0000
21:36214441:GGGTT:G	acceptor_gain	1.0000
21:36214553:A:AG	donor_gain	1.0000
21:36223229:A:AG	acceptor_gain	1.0000
21:36223230:G:GA	acceptor_gain	1.0000
21:36225553:T:TA	acceptor_gain	1.0000
21:36225555:T:TA	acceptor_gain	1.0000
21:36225561:ATAG:A	acceptor_loss	1.0000
21:36225562:T:G	acceptor_gain	1.0000
21:36225563:A:AC	acceptor_loss	1.0000
21:36225563:A:AG	acceptor_gain	1.0000

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000022122 (21:36275568 A>G), RS1000023922 (21:36259103 C>G,T), RS1000029466 (21:36236394 T>G), RS1000034884 (21:36163259 G>A,C), RS1000050374 (21:36186229 G>A), RS1000090031 (21:36242451 A>C), RS1000091108 (21:36199706 G>A,T), RS1000098371 (21:36179846 G>A), RS1000106536 (21:36163492 G>A), RS1000128648 (21:36281295 CAAATA>C,CA), RS1000155259 (21:36190792 G>T), RS1000176369 (21:36292912 C>G), RS1000177253 (21:36221916 G>A), RS1000186014 (21:36264424 A>G,T), RS1000188814 (21:36200742 C>G)

Disease associations

OMIM: gene MIM:604803 | disease phenotypes: MIM:148300

GenCC curated gene-disease

Mondo (1): keratoconus (MONDO:0015486)

Orphanet (2): OBSOLETE: Keratoconus (Orphanet:156071), NON RARE IN EUROPE: Isolated keratoconus (Orphanet:2335)

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0000563	Keratoconus

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D007640	Keratoconus	C11.204.627

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB variants

2 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs112783657	DOP1B	3	0.00	1	cyclophosphamide;epirubicin;fluorouracil
rs74743371	DOP1B	3	0.00	1	cyclophosphamide;epirubicin;fluorouracil

CTD chemical–gene interactions

43 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
arsenite	affects binding, decreases reaction, decreases methylation	2
(+)-JQ1 compound	increases expression	2
Acetaminophen	increases expression	2
Benzo(a)pyrene	decreases expression, increases mutagenesis	2
Cisplatin	decreases expression	2
Estradiol	affects cotreatment, decreases expression	2
FR900359	decreases phosphorylation	1
triphenyl phosphate	affects expression	1
bisphenol A	decreases expression	1
decabromobiphenyl ether	decreases expression	1
tris(2-butoxyethyl) phosphate	affects expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
sodium arsenite	increases abundance, decreases expression	1
tetrabromobisphenol A	decreases expression	1
manganese chloride	increases abundance, increases expression	1
benzo(e)pyrene	decreases methylation	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
aflatoxin B2	affects methylation	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
perfluorooctane sulfonic acid	decreases expression	1
ICG 001	increases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	decreases expression	1
pentabrominated diphenyl ether 100	decreases expression	1
hexabrominated diphenyl ether 153	decreases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Temozolomide	decreases expression	1
Arsenic	decreases expression, increases abundance	1
Caffeine	affects phosphorylation	1
Coumestrol	decreases expression	1
Hydrogen Peroxide	affects expression	1

Clinical trials (associated diseases)

279 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT01485211	PHASE4	COMPLETED	Corneal Thickness Changes During Corneal Collagen Cross-linking With Ultraviolet-A Irradiation and Riboflavin
NCT02119039	PHASE4	COMPLETED	Effect of CACICOL20 on Corneal Epithelial Healing After Cross-linking in Patients With Keratoconus
NCT03245853	PHASE4	COMPLETED	Epi-On Corneal Crosslinking for Keratoconus
NCT03429569	PHASE4	UNKNOWN	Cross-Linking ACcéléré Iontophorèse Confocal kératocONE
NCT04427956	PHASE4	COMPLETED	Corneal Crosslinking Treatment Study
NCT07474870	PHASE4	NOT_YET_RECRUITING	Outcomes of CTAK Surgery
NCT00371202	PHASE3	UNKNOWN	Comparison of Penetrating Keratoplasty and Deep Lamellar Keratoplasty With the Big Bubble Technique for Keratoconus
NCT00647699	PHASE3	COMPLETED	Corneal Collagen Cross-linking for Progressive Keratoconus
NCT00815256	PHASE3	UNKNOWN	Safety and Effectiveness of Collagen Cross Linking in Progressive Mild and Moderate Keratoconus
NCT00887900	PHASE3	COMPLETED	Deep Anterior Lamellar Keratoplasty (DALK)
NCT01112072	PHASE3	UNKNOWN	Corneal Collagen Crosslinking and Intacs for Keratoconus and Ectasia
NCT01152541	PHASE3	UNKNOWN	Corneal Collagen Crosslinking for Progressive Keratoconus and Ectasia Using Riboflavin/Dextran and Hypotonic Riboflavin
NCT01190306	PHASE3	TERMINATED	Safety Study of the VEGA UV-A System to Treat Keratoconus
NCT01344187	PHASE3	COMPLETED	Safety and Efficacy Study of Corneal Collagen Cross-Linking in Eyes With Keratoconus
NCT01459679	PHASE3	TERMINATED	Safety & Efficacy of Corneal Collagen Cross-Linking in Eyes With Keratoconus or Corneal Ectasia After Refractive Surgery
NCT01464268	PHASE3	UNKNOWN	Transepithelial Corneal Collagen Crosslinking for Keratoconus and Corneal Ectasia
NCT01604135	PHASE3	ACTIVE_NOT_RECRUITING	Collagen Crosslinking for Keratoconus - a Randomized Controlled Clinical Trial
NCT01643226	PHASE3	COMPLETED	Safety and Efficacy Study of Corneal Collagen Cross-Linking in Eyes With Keratoconus
NCT01672814	PHASE3	COMPLETED	Microwave Treatment and Corneal Collagen Crosslinking for Keratoconus
NCT01682993	PHASE3	TERMINATED	Corneal Cross Linking and Topography Guided Excimer Laser Treatment
NCT01972854	PHASE3	TERMINATED	Safety and Efficacy of Corneal Collagen Cross-Linking in Eyes With Keratoconus
NCT02613780	PHASE3	UNKNOWN	Refractive Treatment of Early Keratoconus
NCT02638376	PHASE3	UNKNOWN	Evaluating the Safety and Efficacy of the KXL System for Corneal Collagen Cross-Linking in Eyes Having Keratoconus
NCT03080077	PHASE3	UNKNOWN	Safety and Effectiveness of Corneal Crosslinking (CXL): Keratoconus and Post-Refractive Ectasia
NCT03187912	PHASE3	COMPLETED	Accelerated Corneal Cross-linking With Different Riboflavin Solutions
NCT03442751	PHASE3	COMPLETED	Study to Evaluate the Safety and Efficacy of Epi-on Corneal Cross-linking in Eyes With Progressive Keratoconus
NCT03858036	PHASE3	UNKNOWN	Corneal Collagen Cross-Linking (CXL) Performed With Epi-ON Versus Epi-OFF in Eyes With Keratoconus and Other Corneal Ectatic Disorders
NCT04897503	PHASE3	UNKNOWN	Corneal Collagen Crosslinking for Keratoconus and Ectasia Using Riboflavin/Dextran or Riboflavin/Methylcellulose
NCT04905108	PHASE3	UNKNOWN	Transepithelial (Epi-on) Corneal Collagen Crosslinking to Treat Keratoconus and Corneal Ectasia
NCT05027295	PHASE3	UNKNOWN	Accelerated Corneal Collagen Crosslinking for Keratoconus and Ectasia Using Pulse or Continuous UV-A Light
NCT06100939	PHASE3	ACTIVE_NOT_RECRUITING	Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus
NCT06100952	PHASE3	ACTIVE_NOT_RECRUITING	Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age with Keratoconus
NCT06450470	PHASE3	RECRUITING	Use of a Freeze-dried Amniotic Membrane Post Crosslinking in Subjects With Progressive Keratoconus
NCT06601101	PHASE3	RECRUITING	Effects of Topical Insulin on Corneal Epithelium Healing After Corneal Crosslinking in Patients With Keratoconus
NCT07124910	PHASE3	RECRUITING	Comparison of Epi-ON Corneal Collagen Crosslinking Performed Using an 18-Minute UVA Exposure vs. a 24-Minute UVA Exposure on Eyes With Ectatic Corneal Diseases
NCT07135167	PHASE3	RECRUITING	Compassionate Use Study of Epi-ON Corneal Collagen Crosslinking Performed Using UVA Exposure on Eyes With Ectatic Corneal Diseases for Subjects With Down Syndrome
NCT00409955	PHASE2	COMPLETED	Lamellar Transplant With Lyophilized Corneas
NCT00925327	PHASE2	UNKNOWN	Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking for Compassionate Treatment in Pediatric Patients With Progressive Keratoconus
NCT01143389	PHASE2	COMPLETED	Corneal Crosslinking in Patients With Keratoconus and Post-Refractive Ectasia
NCT01181219	PHASE2	COMPLETED	Transepithelial Corneal Collagen Cross-linking (CXL) in Treatment of Keratoconus